Apollo Global Is Said in Talks to Acquire J&J’s Orthopedics Unit
Apollo Global Management is in talks to acquire Johnson & Johnson's orthopedics unit, DePuy Synthes, for around $20 billion. J&J plans to separate the unit, which generated $9.3 billion in sales last year, by mid-2027. Apollo and J&J declined to comment. J&J shares were at $265.58, and Apollo shares rose 0.8% to $128.98.
How this was made
The 30-second read
Why it matters
The announced talks represent the first public indication of a concrete deal size and timeline, offering traders a fresh catalyst.
Market read
First‑report M&A news with $20 billion valuation, likely to move both Apollo and J&J stocks and affect healthcare M&A sentiment.
What to watch
Regulatory scrutiny of large healthcare acquisitions and potential antitrust concerns could delay or block the deal.
Background
Apollo Global Management has been expanding its healthcare portfolio; J&J announced plans to separate its orthopedics business last year.
Ticker impact
Apollo Global Management is in talks to acquire Johnson & Johnson's orthopedics unit DePuy Synthes for about $20 billion.
Apollo may rise on deal optimism; J&J could see modest upside or volatility.
Deal size is material and represents Apollo's biggest healthcare bet; market typically reacts to M&A rumors.
Johnson & Johnson is considering selling its DePuy Synthes orthopedics unit, valued near $20 billion.
JNJ may experience slight upside or stability as investors price in potential cash proceeds.
The transaction is still in discussion; market impact depends on final terms and timing.
Market effects
Healthcare equipment sector may see consolidation pressure; private‑equity interest in medtech rises.
U.S. markets could see increased activity in healthcare and PE stocks.
Large‑scale cross‑border M&A could influence global healthcare M&A sentiment.
Counterpoint
Deal may fall apart, leaving Apollo with sunk due‑diligence costs and J&J may pursue a spin‑off instead.
Key entities
- CompanyApollo Global Management Inc.
Alternative asset manager pursuing acquisition.
- CompanyJohnson & Johnson
Pharma and medical‑technology conglomerate considering divestiture.
- Business UnitDePuy Synthes
J&J's orthopedics division targeted for sale.
